Todd Pitts
Concepts (400)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 24 | 2024 | 792 | 2.830 |
Why?
| | Xenograft Model Antitumor Assays | 38 | 2024 | 864 | 1.960 |
Why?
| | Protein Kinase Inhibitors | 19 | 2020 | 916 | 1.820 |
Why?
| | Triple Negative Breast Neoplasms | 7 | 2024 | 201 | 1.420 |
Why?
| | Antineoplastic Agents | 25 | 2020 | 2129 | 1.410 |
Why?
| | Azepines | 5 | 2024 | 90 | 1.380 |
Why?
| | Histone Deacetylase Inhibitors | 5 | 2024 | 210 | 1.230 |
Why?
| | Cell Line, Tumor | 38 | 2025 | 3399 | 1.160 |
Why?
| | Pyrimidines | 9 | 2020 | 470 | 1.160 |
Why?
| | Mice, Nude | 25 | 2024 | 692 | 1.130 |
Why?
| | Pancreatic Neoplasms | 7 | 2025 | 931 | 1.010 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2025 | 285 | 1.010 |
Why?
| | Pyrazines | 6 | 2018 | 91 | 1.000 |
Why?
| | Cell Proliferation | 22 | 2024 | 2473 | 0.930 |
Why?
| | Apoptosis | 22 | 2024 | 2548 | 0.760 |
Why?
| | Fluorouracil | 1 | 2022 | 210 | 0.740 |
Why?
| | Proto-Oncogene Proteins | 6 | 2018 | 646 | 0.630 |
Why?
| | Benzimidazoles | 6 | 2024 | 168 | 0.620 |
Why?
| | Camptothecin | 5 | 2022 | 114 | 0.620 |
Why?
| | Aurora Kinase A | 4 | 2020 | 56 | 0.620 |
Why?
| | Imidazoles | 4 | 2018 | 239 | 0.610 |
Why?
| | Drug Resistance, Neoplasm | 12 | 2024 | 800 | 0.570 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1683 | 0.550 |
Why?
| | Drug Synergism | 4 | 2014 | 378 | 0.540 |
Why?
| | Mice | 42 | 2025 | 17731 | 0.530 |
Why?
| | Neoplasms | 9 | 2022 | 2644 | 0.490 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 611 | 0.490 |
Why?
| | Cell Cycle Checkpoints | 3 | 2019 | 98 | 0.480 |
Why?
| | Hydroxamic Acids | 3 | 2011 | 89 | 0.480 |
Why?
| | Wnt Signaling Pathway | 5 | 2024 | 192 | 0.480 |
Why?
| | Deoxycytidine | 3 | 2024 | 175 | 0.470 |
Why?
| | Receptor, IGF Type 1 | 3 | 2013 | 65 | 0.460 |
Why?
| | Melanoma | 5 | 2024 | 757 | 0.460 |
Why?
| | Animals | 47 | 2025 | 36768 | 0.450 |
Why?
| | Disease Models, Animal | 11 | 2025 | 4279 | 0.440 |
Why?
| | Pyrazoles | 5 | 2018 | 423 | 0.440 |
Why?
| | Antimitotic Agents | 1 | 2013 | 8 | 0.430 |
Why?
| | Adrenocortical Carcinoma | 3 | 2020 | 65 | 0.430 |
Why?
| | Gene Expression Regulation, Neoplastic | 10 | 2024 | 1396 | 0.430 |
Why?
| | Mitogen-Activated Protein Kinases | 3 | 2014 | 313 | 0.430 |
Why?
| | Tumor Microenvironment | 5 | 2022 | 671 | 0.430 |
Why?
| | Tumor Suppressor Protein p53 | 5 | 2024 | 530 | 0.420 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 413 | 0.420 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 4 | 2022 | 44 | 0.410 |
Why?
| | Signal Transduction | 18 | 2024 | 5065 | 0.410 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2013 | 132 | 0.390 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2018 | 412 | 0.390 |
Why?
| | Boronic Acids | 2 | 2011 | 38 | 0.390 |
Why?
| | Quinoxalines | 4 | 2020 | 66 | 0.370 |
Why?
| | Dasatinib | 2 | 2024 | 54 | 0.360 |
Why?
| | Gene Expression Profiling | 8 | 2024 | 1768 | 0.340 |
Why?
| | Colonic Neoplasms | 2 | 2013 | 256 | 0.340 |
Why?
| | Drug Screening Assays, Antitumor | 5 | 2020 | 193 | 0.340 |
Why?
| | Humans | 68 | 2025 | 136783 | 0.330 |
Why?
| | Heterografts | 3 | 2021 | 138 | 0.330 |
Why?
| | Biomarkers, Tumor | 6 | 2018 | 1274 | 0.330 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2025 | 250 | 0.320 |
Why?
| | Oxidoreductases Acting on CH-CH Group Donors | 2 | 2020 | 26 | 0.310 |
Why?
| | Phosphatidylinositol 3-Kinases | 6 | 2018 | 365 | 0.300 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 2020 | 63 | 0.290 |
Why?
| | Ephrin-B2 | 2 | 2019 | 47 | 0.280 |
Why?
| | Cell Cycle | 7 | 2018 | 601 | 0.280 |
Why?
| | Enzyme Inhibitors | 5 | 2020 | 838 | 0.280 |
Why?
| | Piperazines | 2 | 2020 | 350 | 0.280 |
Why?
| | Quinazolines | 3 | 2015 | 249 | 0.270 |
Why?
| | Drug Delivery Systems | 1 | 2010 | 362 | 0.260 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2024 | 804 | 0.260 |
Why?
| | Anilides | 2 | 2018 | 73 | 0.250 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 3 | 2019 | 134 | 0.250 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2018 | 214 | 0.250 |
Why?
| | Female | 41 | 2025 | 72840 | 0.250 |
Why?
| | Protein-Lysine 6-Oxidase | 1 | 2025 | 14 | 0.240 |
Why?
| | Organoids | 2 | 2024 | 111 | 0.240 |
Why?
| | Gene Dosage | 4 | 2015 | 144 | 0.240 |
Why?
| | Mutation | 9 | 2018 | 3953 | 0.230 |
Why?
| | Nephritis, Interstitial | 1 | 2025 | 14 | 0.230 |
Why?
| | Immunoblotting | 6 | 2015 | 307 | 0.230 |
Why?
| | Cyclosporine | 2 | 2018 | 268 | 0.230 |
Why?
| | Gene Regulatory Networks | 2 | 2024 | 308 | 0.230 |
Why?
| | Collagen Type I | 1 | 2025 | 133 | 0.230 |
Why?
| | Pyrimidinones | 2 | 2015 | 113 | 0.220 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2018 | 226 | 0.220 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2020 | 209 | 0.220 |
Why?
| | RNA, Small Interfering | 2 | 2024 | 621 | 0.220 |
Why?
| | ras Proteins | 4 | 2013 | 151 | 0.210 |
Why?
| | Bevacizumab | 1 | 2024 | 136 | 0.210 |
Why?
| | Endogenous Retroviruses | 1 | 2024 | 36 | 0.210 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 6 | 2016 | 267 | 0.210 |
Why?
| | Receptor, Notch1 | 2 | 2015 | 64 | 0.210 |
Why?
| | Mucous Membrane | 1 | 2024 | 125 | 0.210 |
Why?
| | Pyridones | 2 | 2015 | 168 | 0.210 |
Why?
| | Neoplasm Transplantation | 4 | 2018 | 256 | 0.210 |
Why?
| | Collagen | 1 | 2025 | 445 | 0.200 |
Why?
| | Paclitaxel | 1 | 2024 | 227 | 0.200 |
Why?
| | Pyridines | 2 | 2018 | 505 | 0.200 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2020 | 189 | 0.200 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 66 | 0.200 |
Why?
| | HCT116 Cells | 3 | 2018 | 80 | 0.200 |
Why?
| | Immunotherapy | 3 | 2022 | 640 | 0.190 |
Why?
| | Doxorubicin | 1 | 2024 | 365 | 0.190 |
Why?
| | Drug Design | 2 | 2013 | 166 | 0.190 |
Why?
| | beta Catenin | 2 | 2020 | 251 | 0.180 |
Why?
| | Gene Knockdown Techniques | 4 | 2020 | 326 | 0.180 |
Why?
| | Momordica charantia | 1 | 2020 | 15 | 0.170 |
Why?
| | Benzoxazoles | 1 | 2020 | 19 | 0.170 |
Why?
| | DNA-Binding Proteins | 2 | 2020 | 1500 | 0.170 |
Why?
| | HT29 Cells | 2 | 2018 | 40 | 0.170 |
Why?
| | Neoplasms, Experimental | 2 | 2019 | 176 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 177 | 0.160 |
Why?
| | eIF-2 Kinase | 1 | 2019 | 31 | 0.160 |
Why?
| | src-Family Kinases | 2 | 2017 | 92 | 0.160 |
Why?
| | Inhibitory Concentration 50 | 2 | 2016 | 90 | 0.150 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 34 | 0.150 |
Why?
| | DNA Helicases | 1 | 2020 | 145 | 0.150 |
Why?
| | Tumor Burden | 2 | 2018 | 309 | 0.150 |
Why?
| | Plant Extracts | 1 | 2020 | 200 | 0.150 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 28 | 0.150 |
Why?
| | Coenzymes | 1 | 2018 | 20 | 0.150 |
Why?
| | 4-Aminobenzoic Acid | 1 | 2018 | 7 | 0.150 |
Why?
| | Thermodynamics | 1 | 2020 | 420 | 0.140 |
Why?
| | MAP Kinase Kinase Kinases | 2 | 2015 | 73 | 0.140 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 432 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Adrenal Cortex | 1 | 2018 | 29 | 0.140 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.140 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 507 | 0.140 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 35 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 3 | 2018 | 226 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1463 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2014 | 86 | 0.130 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2016 | 17 | 0.130 |
Why?
| | Cyclopentanes | 1 | 2016 | 20 | 0.130 |
Why?
| | Transplantation, Heterologous | 4 | 2022 | 195 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2024 | 852 | 0.130 |
Why?
| | Tumor Cells, Cultured | 4 | 2020 | 953 | 0.130 |
Why?
| | Corynebacterium | 1 | 2017 | 49 | 0.130 |
Why?
| | Corynebacterium Infections | 1 | 2017 | 41 | 0.130 |
Why?
| | Tankyrases | 1 | 2016 | 15 | 0.130 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2018 | 316 | 0.120 |
Why?
| | Cetuximab | 1 | 2016 | 95 | 0.120 |
Why?
| | Capecitabine | 1 | 2015 | 46 | 0.120 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 121 | 0.120 |
Why?
| | Amyloid Precursor Protein Secretases | 2 | 2013 | 80 | 0.120 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 30 | 0.120 |
Why?
| | Autophagy | 1 | 2018 | 281 | 0.120 |
Why?
| | Drug Discovery | 1 | 2016 | 141 | 0.120 |
Why?
| | Genes, ras | 2 | 2018 | 96 | 0.120 |
Why?
| | Cell Survival | 3 | 2019 | 1117 | 0.120 |
Why?
| | Adenocarcinoma | 2 | 2020 | 936 | 0.120 |
Why?
| | Diphenylamine | 1 | 2014 | 9 | 0.120 |
Why?
| | Gene Expression Regulation | 1 | 2024 | 2603 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 182 | 0.110 |
Why?
| | Germ-Line Mutation | 2 | 2018 | 172 | 0.110 |
Why?
| | Piperidines | 1 | 2015 | 205 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2014 | 75 | 0.110 |
Why?
| | Middle Aged | 14 | 2024 | 33200 | 0.110 |
Why?
| | Benzamides | 1 | 2014 | 217 | 0.110 |
Why?
| | Protein Kinases | 1 | 2015 | 319 | 0.110 |
Why?
| | Up-Regulation | 1 | 2016 | 843 | 0.100 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2016 | 250 | 0.100 |
Why?
| | Tetrahydronaphthalenes | 1 | 2013 | 29 | 0.100 |
Why?
| | Receptor, Insulin | 1 | 2013 | 105 | 0.100 |
Why?
| | Aged | 11 | 2024 | 23729 | 0.100 |
Why?
| | Valine | 1 | 2013 | 82 | 0.100 |
Why?
| | Neutrophils | 4 | 2019 | 1234 | 0.100 |
Why?
| | Bortezomib | 2 | 2011 | 54 | 0.100 |
Why?
| | Receptors, Notch | 1 | 2013 | 88 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 327 | 0.100 |
Why?
| | Mitosis | 1 | 2013 | 193 | 0.100 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2013 | 190 | 0.090 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 145 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 100 | 0.090 |
Why?
| | Sirolimus | 1 | 2013 | 275 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 45 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 682 | 0.090 |
Why?
| | Head and Neck Neoplasms | 1 | 2016 | 604 | 0.090 |
Why?
| | Computational Biology | 1 | 2015 | 645 | 0.090 |
Why?
| | Benzodioxoles | 1 | 2012 | 115 | 0.090 |
Why?
| | Protease Inhibitors | 1 | 2011 | 106 | 0.080 |
Why?
| | Carcinogenesis | 2 | 2024 | 217 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2018 | 436 | 0.080 |
Why?
| | Mice, Inbred NOD | 2 | 2022 | 601 | 0.080 |
Why?
| | Phosphorylation | 4 | 2019 | 1756 | 0.080 |
Why?
| | Neoplasm Metastasis | 3 | 2018 | 654 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2015 | 710 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 7 | 0.080 |
Why?
| | Adult | 12 | 2024 | 37616 | 0.080 |
Why?
| | Mice, Inbred BALB C | 3 | 2020 | 1267 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 71 | 0.080 |
Why?
| | Breast Neoplasms | 2 | 2012 | 2239 | 0.080 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 95 | 0.070 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2009 | 77 | 0.070 |
Why?
| | Cell Movement | 2 | 2011 | 969 | 0.070 |
Why?
| | Male | 15 | 2024 | 67361 | 0.070 |
Why?
| | Positron-Emission Tomography | 3 | 2018 | 295 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 890 | 0.070 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2011 | 360 | 0.070 |
Why?
| | Prognosis | 4 | 2019 | 4018 | 0.070 |
Why?
| | Farnesyltranstransferase | 1 | 2007 | 35 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 765 | 0.060 |
Why?
| | Feasibility Studies | 1 | 2010 | 947 | 0.060 |
Why?
| | Protein Conformation | 2 | 2020 | 940 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2024 | 167 | 0.060 |
Why?
| | Gene Expression | 2 | 2019 | 1499 | 0.060 |
Why?
| | Algorithms | 3 | 2024 | 1686 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2024 | 1453 | 0.060 |
Why?
| | Maximum Tolerated Dose | 2 | 2020 | 198 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3272 | 0.060 |
Why?
| | Quinolones | 1 | 2007 | 137 | 0.060 |
Why?
| | Ipilimumab | 1 | 2025 | 33 | 0.060 |
Why?
| | Neovascularization, Pathologic | 2 | 2018 | 301 | 0.060 |
Why?
| | Disease Progression | 2 | 2025 | 2750 | 0.060 |
Why?
| | CTLA-4 Antigen | 1 | 2025 | 99 | 0.060 |
Why?
| | Models, Molecular | 2 | 2020 | 1591 | 0.050 |
Why?
| | Structure-Activity Relationship | 2 | 2018 | 573 | 0.050 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2019 | 40 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 147 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2024 | 190 | 0.050 |
Why?
| | HMGB1 Protein | 1 | 2003 | 50 | 0.050 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2002 | 28 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2002 | 45 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2002 | 34 | 0.050 |
Why?
| | Neuroimmunomodulation | 1 | 2002 | 65 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2018 | 616 | 0.050 |
Why?
| | Histone Deacetylase 1 | 1 | 2022 | 25 | 0.050 |
Why?
| | Isoenzymes | 1 | 2003 | 304 | 0.050 |
Why?
| | Aurora Kinases | 2 | 2012 | 27 | 0.050 |
Why?
| | Histones | 2 | 2022 | 635 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2024 | 10764 | 0.050 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 133 | 0.050 |
Why?
| | Endotoxemia | 1 | 2002 | 86 | 0.050 |
Why?
| | Caspase 3 | 2 | 2013 | 246 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2417 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 31 | 0.040 |
Why?
| | Acetylation | 1 | 2022 | 248 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2025 | 527 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2019 | 1181 | 0.040 |
Why?
| | Campylobacter jejuni | 1 | 2000 | 12 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 87 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 75 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2012 | 495 | 0.040 |
Why?
| | Catalase | 1 | 2000 | 131 | 0.040 |
Why?
| | TCF Transcription Factors | 1 | 2020 | 17 | 0.040 |
Why?
| | Histone Deacetylases | 1 | 2022 | 214 | 0.040 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2002 | 323 | 0.040 |
Why?
| | RNA, Neoplasm | 1 | 2020 | 82 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 367 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2020 | 94 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
| | Indolizines | 1 | 2019 | 4 | 0.040 |
Why?
| | Forkhead Box Protein M1 | 1 | 2019 | 7 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 125 | 0.040 |
Why?
| | Small Molecule Libraries | 1 | 2020 | 95 | 0.040 |
Why?
| | MAP Kinase Kinase 2 | 2 | 2013 | 28 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 790 | 0.040 |
Why?
| | MAP Kinase Kinase 1 | 2 | 2013 | 75 | 0.040 |
Why?
| | Crystallography, X-Ray | 1 | 2020 | 485 | 0.040 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
| | Genetic Linkage | 1 | 1999 | 298 | 0.040 |
Why?
| | High-Throughput Screening Assays | 1 | 2020 | 160 | 0.040 |
Why?
| | Flavin-Adenine Dinucleotide | 1 | 2018 | 16 | 0.040 |
Why?
| | NADP | 1 | 2018 | 50 | 0.040 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 209 | 0.040 |
Why?
| | Radiotherapy | 1 | 2019 | 201 | 0.040 |
Why?
| | Nausea | 1 | 2018 | 111 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 44 | 0.040 |
Why?
| | Multifactorial Inheritance | 1 | 1999 | 174 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 891 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 313 | 0.030 |
Why?
| | Hemorrhage | 1 | 2002 | 723 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1059 | 0.030 |
Why?
| | Breast | 1 | 2018 | 150 | 0.030 |
Why?
| | DNA Damage | 1 | 2020 | 418 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 183 | 0.030 |
Why?
| | Catalytic Domain | 1 | 2018 | 226 | 0.030 |
Why?
| | RNA | 1 | 2024 | 924 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1354 | 0.030 |
Why?
| | Autistic Disorder | 1 | 1999 | 201 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 687 | 0.030 |
Why?
| | Axin Protein | 1 | 2016 | 19 | 0.030 |
Why?
| | Ubiquitination | 1 | 2016 | 102 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 327 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 387 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 400 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2020 | 2831 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 808 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 451 | 0.030 |
Why?
| | Hypertension | 2 | 2018 | 1284 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 23 | 0.030 |
Why?
| | Tumor Protein p73 | 1 | 2015 | 14 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 615 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 68 | 0.030 |
Why?
| | Binding Sites | 1 | 2018 | 1308 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1126 | 0.030 |
Why?
| | NF-kappa B | 3 | 2003 | 691 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1731 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2015 | 236 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 218 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 2999 | 0.030 |
Why?
| | Caspase 7 | 1 | 2013 | 22 | 0.030 |
Why?
| | Butadienes | 1 | 2013 | 36 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 379 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2013 | 50 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1319 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 34 | 0.030 |
Why?
| | Everolimus | 1 | 2013 | 91 | 0.020 |
Why?
| | Nitriles | 1 | 2013 | 172 | 0.020 |
Why?
| | Random Allocation | 1 | 2013 | 353 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 913 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3199 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 155 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 2 | 2003 | 145 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1373 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2003 | 282 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2013 | 249 | 0.020 |
Why?
| | Kinetics | 1 | 2014 | 1668 | 0.020 |
Why?
| | Enzyme Activation | 2 | 2003 | 813 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2012 | 317 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 162 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2012 | 187 | 0.020 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2010 | 14 | 0.020 |
Why?
| | Receptor, ErbB-2 | 1 | 2012 | 342 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2010 | 67 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 155 | 0.020 |
Why?
| | Population Groups | 1 | 2010 | 62 | 0.020 |
Why?
| | Neutropenia | 1 | 2010 | 146 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 111 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2010 | 144 | 0.020 |
Why?
| | Metabolome | 1 | 2013 | 350 | 0.020 |
Why?
| | Ligands | 1 | 2011 | 664 | 0.020 |
Why?
| | Drug Combinations | 1 | 2010 | 344 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 340 | 0.020 |
Why?
| | Keratinocytes | 1 | 2010 | 248 | 0.020 |
Why?
| | Transcriptome | 1 | 2015 | 971 | 0.020 |
Why?
| | Australia | 1 | 2010 | 314 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2015 | 1162 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2015 | 1428 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4158 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 973 | 0.020 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2007 | 14 | 0.020 |
Why?
| | Sulfonamides | 1 | 2011 | 512 | 0.020 |
Why?
| | Verapamil | 1 | 2007 | 41 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 849 | 0.020 |
Why?
| | Calcium | 1 | 2013 | 1197 | 0.020 |
Why?
| | Blotting, Western | 1 | 2009 | 1225 | 0.020 |
Why?
| | Clone Cells | 1 | 2007 | 266 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2045 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3566 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 2007 | 167 | 0.020 |
Why?
| | Family | 1 | 2010 | 666 | 0.020 |
Why?
| | Metabolomics | 1 | 2011 | 679 | 0.010 |
Why?
| | MicroRNAs | 1 | 2012 | 697 | 0.010 |
Why?
| | Cohort Studies | 1 | 2015 | 5718 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 2011 | 784 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 563 | 0.010 |
Why?
| | Phosphotransferases | 1 | 2003 | 24 | 0.010 |
Why?
| | Class Ib Phosphatidylinositol 3-Kinase | 1 | 2003 | 4 | 0.010 |
Why?
| | bcl-Associated Death Protein | 1 | 2003 | 9 | 0.010 |
Why?
| | Phentolamine | 1 | 2002 | 15 | 0.010 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2002 | 21 | 0.010 |
Why?
| | Brimonidine Tartrate | 1 | 2002 | 10 | 0.010 |
Why?
| | Propranolol | 1 | 2002 | 50 | 0.010 |
Why?
| | Phenylephrine | 1 | 2002 | 75 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 2003 | 298 | 0.010 |
Why?
| | Adolescent | 2 | 2018 | 21463 | 0.010 |
Why?
| | Chemokines | 1 | 2003 | 228 | 0.010 |
Why?
| | Peroxidase | 1 | 2002 | 176 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 152 | 0.010 |
Why?
| | Biological Transport | 1 | 2003 | 411 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 233 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 135 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 13126 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2000 | 16 | 0.010 |
Why?
| | omega-N-Methylarginine | 1 | 2000 | 27 | 0.010 |
Why?
| | MAP Kinase Signaling System | 1 | 2002 | 321 | 0.010 |
Why?
| | Inflammation Mediators | 1 | 2003 | 514 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 467 | 0.010 |
Why?
| | Statistical Distributions | 1 | 1999 | 8 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2000 | 534 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 1999 | 40 | 0.010 |
Why?
| | Intelligence Tests | 1 | 1999 | 59 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 1999 | 44 | 0.010 |
Why?
| | Nuclear Family | 1 | 1999 | 54 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2003 | 885 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2002 | 434 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2000 | 320 | 0.010 |
Why?
| | Linkage Disequilibrium | 1 | 1999 | 268 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2003 | 768 | 0.010 |
Why?
| | Models, Genetic | 1 | 1999 | 605 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2003 | 4194 | 0.010 |
Why?
| | Cell Line | 1 | 2000 | 2836 | 0.010 |
Why?
| | Cytokines | 1 | 2003 | 2088 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1999 | 2903 | 0.010 |
Why?
| | Genotype | 1 | 1999 | 1919 | 0.010 |
Why?
| | Sex Factors | 1 | 1999 | 2068 | 0.010 |
Why?
| | Macrophages | 1 | 2000 | 1541 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2003 | 5744 | 0.010 |
Why?
| | Child, Preschool | 1 | 1999 | 11069 | 0.000 |
Why?
| | Child | 1 | 1999 | 21968 | 0.000 |
Why?
|
|
Pitts's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|